Gapping down
M&A news: GTSI -44.3% (Eyak Technology announces withdrawal of proposal to co for $7.50 per share), CCE -29.9% (Coca-Cola finalizes transaction with Coca-Cola Enterprises; completed the acquisition of the North American operations of CCE and the sale of the co's Norway and Sweden bottling operations to CCE ).
Select metals/mining stocks trading lower: MT -3.6%, NXG -3.0%, AAU -2.4%, AU -1.7%, RTP -1.7%, GSS -1.6%, HL -1.3%, BHP -1.3%.
Select oil/gas related names showing weakness: TOT -2.2%, RDS.A -1.6%, E -1.6%, BP -1.5%.
Other news: XRA -7.1% (to finance CAD50 mln bought deal of 8,065,000 common shares of the co at a price of CAD6.20 ), CVVT -3.9% (ticking lower; Hearing attributed to boutique firm downgrade).
Analyst comments: XL -2.3% (downgraded to Neutral from Outperform at Credit Suisse), JCP -2.0% (downgraded to Neutral from Buy at Goldman), M -1.9% (downgraded to Neutral from Buy at Goldman), SPWRA -1.8% (downgraded to Sell from Hold at Canaccord Genuity), MSFT -1.7% (downgraded to Neutral from Buy at Goldman), SMG -1.6% (downgraded to Neutral from Buy at Suntrust), FOSL -1.6% (downgraded to Neutral from Buy at SunTrust), FCX -1.0% (removed from Top Picks Live list at Citigroup).
Gapping up
In reaction to guidance: TSTC +3.1% (light volume; secured a 300 mln RMB line of credit from Bank of Beijing; reaffirms FY10 revenue guidance of $129.4 mln vs single est of $111.1 mln).
M&A news: DDMX +37.8% (enters into definitive agreement to be acquired by Greenbriar Equity Group for $21.25 Per Share in Cash), ACTL +30.1% (Actel acquired by Microsemi for $20.88/share; $0.22-0.28 accretive in its first full calendar; MSCC re-affirms Q4 EPS guidance; sees Q4 revs in line), MIM + 18.1% (ST Acquisition Corp intends to make an offer to acquire any or all of the Class A Subordinate Voting Shares and Class B Shares of co not already owned by it or its affiliates and associates at a price of $13.00 per share in cash).
Other news: XPO +38.2% (still checking; continued momentum), ARRY +16.1% (announces positive results for HER2 inhibitor, ARRY-380, in breast cancer patients), SLE +11.7% (trading over 10% higher in premarket following reports out over the weekend that the co rejected takeover bid from KKR), ISLN +11.6% (ticking higher; hearing co is seeking out buyers), GKK +9.3% (announces offer to purchase Series A preferred shares), F +2.0% (still checking; Hearing intitiated with Overweight at tier 1 firm), ASML +1.6% (still checking).
Analyst comments: JASO +1.0% (upgraded to Buy from Hold at Canaccord Genuity).